Clinical Trials Logo

Carcinoma, Merkel Cell clinical trials

View clinical trials related to Carcinoma, Merkel Cell.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT03228667 Active, not recruiting - Colorectal Cancer Clinical Trials

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Start date: December 11, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase IIb, multicohort, open-label multicenter study of combination immunotherapies in patients who have previously received treatment with PD-1/PD-L1 immune checkpoint inhibitors. All patients in Cohorts 1-4 will receive the combination treatment of PD-1/PD-L1 checkpoint inhibitor plus N-803 for up to 17 cycles. Each cycle is six weeks in duration. Some patients who experience disease progression while on study in Cohorts 1-4 may roll over into Cohort 5 and receive combination therapy with a PD-1/PD-L1 checkpoint inhibitor, N-803, and PD-L1 t-haNK cellular therapy for up to an additional 17 cycles. Each cycle is six weeks in duration. All patients will receive N-803 once every 3 weeks. Patients will also receive the same checkpoint inhibitor that they received during their previous therapy. Radiologic evaluation will occur at the end of each treatment cycle. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months past administration of the first dose of study drug.

NCT ID: NCT03074513 Active, not recruiting - Clinical trials for Neuroendocrine Carcinoma

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

Start date: March 3, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT03071406 Active, not recruiting - Skin Cancer Clinical Trials

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

Start date: March 14, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the effectiveness, safety, and tolerability of the drugs nivolumab plus ipilimumab with or without the addition of stereotactic body radiation therapy (SBRT). Nivolumab is an antibody (a type of human protein) that is being tested to see if it will stimulate the body's immune system to work against tumor cells. This study will test an investigational use of nivolumab.

NCT ID: NCT02978625 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

Start date: September 27, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.

NCT ID: NCT02196961 Active, not recruiting - Clinical trials for Merkel Cell Carcinoma

Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies vs Observation

ADMEC-O
Start date: June 2014
Phase: Phase 2
Study type: Interventional

Primary objective: To estimate the efficacy of adjuvant nivolumab monotherapy in completely resected MCC patients Primary endpoint: Disease-free survival (DFS) rate evaluated at 12, 24 and 48 months after date of randomization Secondary Objectives: To describe the safety profile and additional efficacy parameters of the nivolumab treatment in MCC Secondary endpoints: - Adverse events according to CTCAE, Version 4.0 criteria, that are related to the administration of nivolumab - Disease-free survival (DFS) - Overall survival (OS) and OS rates at 12, 24 and 48 months after randomization Explorative Endpoints: - Distant-metastases-free survival (DMFS) and DMFS rate at 12, 24 and 48 months after randomization - Identification and validation of prognostic/predictive biomarkers - Quality of life (EORTC QLQ-C30) until 24 months after randomization

NCT ID: NCT00436735 Active, not recruiting - Colorectal Cancer Clinical Trials

Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors

Start date: September 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Nelfinavir may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of nelfinavir in treating patients with metastatic, refractory, or recurrent solid tumors.